FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities researchers at Roth Capital lowered their FY2028 earnings per share (EPS) estimates for shares of Nuvectis Pharma in a research note issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $3.23 for the year, down from their previous forecast of $3.61. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s FY2029 earnings at $4.24 EPS.

Separately, HC Wainwright reduced their price target on Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday.

Nuvectis Pharma Price Performance

NVCT opened at $6.86 on Thursday. The business has a 50 day simple moving average of $6.22 and a 200-day simple moving average of $6.41. The stock has a market capitalization of $132.54 million, a P/E ratio of -5.91 and a beta of 0.22. Nuvectis Pharma has a 12 month low of $4.44 and a 12 month high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP raised its holdings in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after purchasing an additional 1,790 shares during the last quarter. Baxter Bros Inc. raised its holdings in Nuvectis Pharma by 20.0% during the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after purchasing an additional 2,500 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its position in Nuvectis Pharma by 35.0% during the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock worth $73,000 after buying an additional 3,500 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Nuvectis Pharma during the fourth quarter worth $34,000. Finally, Northern Trust Corp increased its position in Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company’s stock worth $139,000 after buying an additional 10,472 shares in the last quarter. 96.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of Nuvectis Pharma stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average cost of $5.00 per share, with a total value of $1,200,000.00. Following the completion of the acquisition, the insider now owns 2,884,121 shares in the company, valued at $14,420,605. This trade represents a 9.08 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders bought 261,500 shares of company stock valued at $1,300,825. 35.78% of the stock is owned by insiders.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.